Video

REVIEW UroToday

Immunotherapy PCa VL

Search

Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly Details Kevin Kelly discusses a groundbreaking approach to prostate cancer treatment with Alicia Morgans. He presents Xaluritamig (AMG 509) a novel bi-specific antibody targeting the STEAP1 protein, prevalent in prostate cancer cells. This innovative therapy, a form of biTE therapy, is designed to attract T-cells for targeted cytotoxicity. In a phase one trial involving advanced prostate cancer patients w...
Investigating the Role and Therapeutic Potential of B7-H3 in Prostate Cancer - Christina Guo Details Christina Guo elaborates on her and her colleagues' findings published in European Urology, titled "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer". Dr. Guo's research focuses on B7-H3, an immunomodulatory glycoprotein overexpressed in prostate cancers. The team investigated B7-H3 expression in treatment-naive and castration-resistant prostate cancer biopsies, analyzing the protein's co...
Targeting Tumor-Induced Neutrophil Senescence: A Novel Approach to Treating Prostate Cancer - Arianna Calcinotto & Nicolo Bancaro Details Andrea Miyahira speaks with Arianna Calcinotto and Nicolo Bancaro about their groundbreaking research on the role of senescent neutrophils in prostate cancer. Calcinotto's team discovered that prostate tumor cells produce a molecule, ApoE, which can bind to and influence a type of immune cells, neutrophils, resulting in these cells acquiring senescent, or aged features. They also found that these...